Related Experiment Videos
Sweet's syndrome associated with granulocyte colony-stimulating factor
1Drug Safety Department, Hoffmann La Roche Ltd., Basel, Switzerland.
Cutis
|February 1, 1996
Summary
Sweet's syndrome is linked to serious diseases and can be an adverse drug reaction. It is particularly associated with Filgrastim, a type of recombinant human granulocyte colony-stimulating factor.
Area of Science:
- Dermatology
- Oncology
- Pharmacology
Background:
- Sweet's syndrome, also known as acute febrile neutrophilic dermatosis, is an inflammatory condition.
- It has been associated with various underlying systemic diseases.
Purpose of the Study:
- To review the association between Sweet's syndrome and malignant and inflammatory diseases.
- To highlight drug-induced Sweet's syndrome, focusing on recombinant human granulocyte colony-stimulating factor (Filgrastim).
Main Methods:
- Literature review of reported cases and associations.
- Analysis of clinical data linking Sweet's syndrome to specific conditions and medications.
Main Results:
- Sweet's syndrome frequently occurs in patients with underlying malignant or inflammatory conditions.
- Recombinant human granulocyte colony-stimulating factor (Filgrastim) is identified as a significant trigger for drug-induced Sweet's syndrome.
Conclusions:
- Sweet's syndrome serves as a potential indicator for underlying systemic diseases.
- Awareness of drug-induced Sweet's syndrome, especially with Filgrastim, is crucial for clinical management.